FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022205993> ?p ?o ?g. }

• W2022205993 endingPage "77" @default.
• W2022205993 startingPage "69" @default.
• W2022205993 abstract "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative progressive currently untreatable disease, characterized by selective motor neuron degeneration; the incidence and prevalence of ALS are greater in men than in women. Although some important mechanisms that might contribute to the death of motor neurons have been identified, the mechanisms underlying disease pathophysiology are still uncertain. In particular, the mechanisms underlying the role of gender in ALS and whether treatments should take into account sexual dimorphism remain only partially understood. Recently, the P2X7 receptor for ATP was reported to display neurotoxic potential in motor neuron disorders, and antagonism of the receptor has been suggested to be helpful in these disorders. Studying transgenic mice with superoxide dismutase 1 gene mutations, widely used as model for ALS, may provide a better understanding of pathogenic mechanisms and of toxicity towards motor neurons, also possibly helping to understand whether treatments for ALS should take into account sexual dimorphism. The aim of the work was (1) investigating on gender-dependence of disease progression in the standard model for ALS – the transgenic mouse bearing superoxide dismutase 1 gene mutations – and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism. We evaluated if gender affect the disease course, the motor performance, the weight loss and the lifespan in mice overexpressing mutant superoxide dismutase 1. We measured motor impairment, motor strength and coordination by rotarod and grip strength testing. Further, we assessed if a treatment with the P2X7 receptor antagonist Brilliant Blue G – a dye that can cross the blood–brain barrier, has low toxicity, and has exhibited therapeutic effects in animal models of neurodegenerative diseases – impact on the disease progression, in male and female ALS mice. We found that (1) the onset and the disease progression, and the survival were dependent on gender: male performed worst than female, lost body weight and died before; (2) treatment with the P2X7 receptor antagonist Brilliant Blue G ameliorated the disease progression. The treatment effect was gender-dependent: amelioration was greater in male than in female. In conclusions, we suggest that not only pathogenetic mechanism of motor neuron toxicity but also the drug treatment effectiveness may depend on gender; sexual dimorphism should be considered when investigating on ALS treatment efficacy in the ALS animal model. Our findings also point on the potential relevance of P2X7 receptor antagonism for ALS treatment, and highlight the importance of adopting a sex-specific approach to searching for treatment of ALS." @default.
• W2022205993 created "2016-06-24" @default.
• W2022205993 creator A5016839349 @default.
• W2022205993 creator A5034874559 @default.
• W2022205993 creator A5067431506 @default.
• W2022205993 creator A5090410872 @default.
• W2022205993 date "2013-09-01" @default.
• W2022205993 modified "2023-09-30" @default.
• W2022205993 title "Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism" @default.
• W2022205993 cites W1493853215 @default.
• W2022205993 cites W1505009538 @default.
• W2022205993 cites W1553995814 @default.
• W2022205993 cites W1897243328 @default.
• W2022205993 cites W1899748273 @default.
• W2022205993 cites W1965622382 @default.
• W2022205993 cites W1971817436 @default.
• W2022205993 cites W1978885930 @default.
• W2022205993 cites W1990541678 @default.
• W2022205993 cites W1995270458 @default.
• W2022205993 cites W1997142506 @default.
• W2022205993 cites W1997874493 @default.
• W2022205993 cites W2001393056 @default.
• W2022205993 cites W2007336957 @default.
• W2022205993 cites W2009725722 @default.
• W2022205993 cites W2010666651 @default.
• W2022205993 cites W2011374209 @default.
• W2022205993 cites W2014680810 @default.
• W2022205993 cites W2018231959 @default.
• W2022205993 cites W2019702139 @default.
• W2022205993 cites W2021706455 @default.
• W2022205993 cites W2023582781 @default.
• W2022205993 cites W2028240691 @default.
• W2022205993 cites W2033158384 @default.
• W2022205993 cites W2040566930 @default.
• W2022205993 cites W2041069934 @default.
• W2022205993 cites W2042556208 @default.
• W2022205993 cites W2045901798 @default.
• W2022205993 cites W2050016412 @default.
• W2022205993 cites W2053410363 @default.
• W2022205993 cites W2056123178 @default.
• W2022205993 cites W2058313056 @default.
• W2022205993 cites W2062817102 @default.
• W2022205993 cites W2063771518 @default.
• W2022205993 cites W2067977709 @default.
• W2022205993 cites W2068201081 @default.
• W2022205993 cites W2069219003 @default.
• W2022205993 cites W2071751113 @default.
• W2022205993 cites W2076461577 @default.
• W2022205993 cites W2078936076 @default.
• W2022205993 cites W2079662823 @default.
• W2022205993 cites W2083040497 @default.
• W2022205993 cites W2085656073 @default.
• W2022205993 cites W2086652283 @default.
• W2022205993 cites W2094760723 @default.
• W2022205993 cites W2098109360 @default.
• W2022205993 cites W2102238895 @default.
• W2022205993 cites W2104986316 @default.
• W2022205993 cites W2106315408 @default.
• W2022205993 cites W2107768418 @default.
• W2022205993 cites W2116683252 @default.
• W2022205993 cites W2122574609 @default.
• W2022205993 cites W2123640958 @default.
• W2022205993 cites W2128556409 @default.
• W2022205993 cites W2130476218 @default.
• W2022205993 cites W2138447230 @default.
• W2022205993 cites W2139521371 @default.
• W2022205993 cites W2144507462 @default.
• W2022205993 cites W2152089134 @default.
• W2022205993 cites W2153177211 @default.
• W2022205993 cites W2156346381 @default.
• W2022205993 cites W2163992233 @default.
• W2022205993 cites W2165709201 @default.
• W2022205993 cites W2174061466 @default.
• W2022205993 cites W2913609543 @default.
• W2022205993 cites W4231401157 @default.
• W2022205993 doi "https://doi.org/10.1016/j.tox.2013.04.004" @default.
• W2022205993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23583883" @default.
• W2022205993 hasPublicationYear "2013" @default.
• W2022205993 type Work @default.
• W2022205993 sameAs 2022205993 @default.
• W2022205993 citedByCount "50" @default.
• W2022205993 countsByYear W20222059932013 @default.
• W2022205993 countsByYear W20222059932014 @default.
• W2022205993 countsByYear W20222059932015 @default.
• W2022205993 countsByYear W20222059932016 @default.
• W2022205993 countsByYear W20222059932017 @default.
• W2022205993 countsByYear W20222059932018 @default.
• W2022205993 countsByYear W20222059932019 @default.
• W2022205993 countsByYear W20222059932020 @default.
• W2022205993 countsByYear W20222059932021 @default.
• W2022205993 countsByYear W20222059932022 @default.
• W2022205993 countsByYear W20222059932023 @default.
• W2022205993 crossrefType "journal-article" @default.
• W2022205993 hasAuthorship W2022205993A5016839349 @default.
• W2022205993 hasAuthorship W2022205993A5034874559 @default.
• W2022205993 hasAuthorship W2022205993A5067431506 @default.
• W2022205993 hasAuthorship W2022205993A5090410872 @default.
• W2022205993 hasConcept C102230213 @default.

• next